News Headlines

1. Pharmaceutics International, Inc. (Pii) – A Key Part Of The FDA’s 503B Solution 7/2/2020

   Pharmaceutics International, Inc. (Pii) has been added to the FDA’s list of organizations officially registered as human drug outsourcing facilities under the updated requirements of Section 503B of the Federal Food, Drug, and Cosmetic Act (FD&C Act).

2. Thermo Fisher Scientific And CSL Enter Strategic Partnership To Provide Best-In-Class Pharma Services 7/1/2020

   Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, and global biotechnology company, CSL Limited (ASX:CSL;USOTC:CSLLY) today announced they have entered into a strategic partnership to help meet the growing demand for biologic therapies while also accelerating CSL's broader manufacturing objectives.

3. Lonza Expands Particle Engineering Services 7/1/2020

   Lonza announced additional investments in its global particle engineering network for expanded capacity and specialized capabilities.  Jet milling and spray dry processing for development have been significantly expanded at US and European sites to meet increased demand. Specialized processing capabilities have also been enhanced.

4. Grand River Aseptic Manufacturing Opens Large-Scale Injectable Fill/Finish Facility, Significantly Increasing Capacity 6/30/2020

   Grand River Aseptic Manufacturing (“GRAM”), an agile and modern parenteral contract development and manufacturing organization (CDMO), completed its major $60M expansion project and recently took occupancy.

5. Advanced Accelerator Applications To Build Targeted RadioLigand Therapy Production Facility In Indianapolis 6/30/2020

   Advanced Accelerator Applications S.A. (AAA), a Novartis company, today announced it has executed a sales and purchase agreement for land on which a 50,000 square foot targeted Radioligand Therapy (RLT) manufacturing plant will be built.

6. CDMO Grand River Aseptic Manufacturing Opens Large-Scale Injectable Fill/Finish Facility In Michigan With Increased Capacity 6/30/2020

   Grand River Aseptic Manufacturing (“GRAM”), an agile and modern parenteral contract development and manufacturing organization (CDMO), completed its major $60M expansion project and recently took occupancy.

7. Ajinomoto Bio-Pharma Services Introduces AJILITY Fast Track Platform For Drug Product Manufacturing 6/30/2020

   Ajinomoto Bio-Pharma Services (“Aji Bio-Pharma”), a leading provider of biopharmaceutical contract development and manufacturing services, is pleased to announce the launch of AJILITY™, a flexible and agile drug product manufacturing platform, designed to advance vaccines and therapies to market by minimizing time to production.

8. Jones Healthcare Group Adds New Uhlmann Bottling Line To Expand Capabilities 6/29/2020

   Jones Healthcare Group, a market leader in advanced packaging and medication dispensing solutions, today announces expanded bottling capabilities within its packaging services portfolio. The company’s investment in a new, fully integrated Uhlmann bottle line enhances its multi-level service offering across all package formats for healthcare clients.

9. Moderna And Catalent Announce Collaboration For Fill-Finish Manufacturing Of Moderna’s COVID-19 Vaccine Candidate 6/25/2020

   Moderna, Inc., a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, and Catalent, Inc., the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced a collaboration for large-scale, commercial fill-finish manufacturing of Moderna’s mRNA-based COVID-19 vaccine candidate (mRNA-1273) at Catalent’s biologics facility in Bloomington, Indiana.

10. Gilead Sciences Secures Exclusive Option To Acquire Pionyr Immunotherapeutics 6/23/2020

    Gilead Sciences, Inc. announced today that for $275M the company will acquire a 49.9 percent equity interest in Pionyr Immunotherapeutics Inc., a privately held company developing first-in-class cancer immunotherapies, and an exclusive option to purchase the remainder of Pionyr.